Sugi Predict

Sugi Predict / Compounds / SCHEMBL4294152

SCHEMBL4294152

SCHEMBL4294152

CCCC[Sn](CCCC)(CCCC)c1sc(NC(=O)OC(C)(C)C)nc1COC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ LCK P06239 10/20 0.36
▸ PI4KB Q9UBF8 1/20 0.35
▸ TSHR P16473 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ NFKB1 P19838 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ STAT1 P42224 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC7 Q8WUI4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4301594 0.85 MAPT (0.37) TSHRMAPTNPC1ALDH1A1CYP1A2
SCHEMBL25389524 0.84 LCK (0.46) CA1CA2LCKPI4KBTSHR
SCHEMBL1741900 0.76 LCK (0.45) CA1CA2LCKPI4KBTSHR
SCHEMBL2174730 0.74 CA1 (0.40) CA1CA2LCKPI4KB
SCHEMBL17331772 0.73 PI4KB (0.43) CA1CA2LCKPI4KBTSHR
SCHEMBL1094706 0.72 CCNE1 (0.40) CA1CA2LCKPI4KBRAB9A
SCHEMBL24434724 0.71 NPC1 (0.55) CA1CA2LCKPI4KBNPC1
SCHEMBL31661298 0.70 LCK (0.46) CA1CA2LCKPI4KBTSHR
SCHEMBL31661308 0.70 LCK (0.46) CA1CA2LCKPI4KBTSHR
SCHEMBL25484165 0.69 NPC1 (0.45) CA1CA2LCKPI4KBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 — — EP disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 — — US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 — — US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 — — US disclosed
EP-1981884-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS Amgen, Inc (US) 2008-10-22 — — EP disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 — — WO disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 CA1 3657/4885CA2 1110/4885LCK 313/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 CA1 3346/4885CA2 904/4885LCK 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.